Archive · 14 Sep 2026
Nafisa Ali Sodhi Changes Cancer Treatment After Disease Progression
Nafisa Ali Sodhi said her cancer treatment has changed to targeted therapy.
She also said a scan suggested that her ovarian or peritoneal cancer had progressed.
This means the cancer may have grown or appeared in new areas despite treatment.
The scan showed new deposits on the outside surface of her liver.
This is different from a tumor growing inside the liver.
Chemotherapy attacks many rapidly dividing cells in the body.
Targeted therapy is designed to attack specific features that help cancer cells grow.
Doctors may recommend targeted therapy only when testing shows that it could work for a particular cancer.
Doctors also review scans, symptoms, examinations, and previous treatments before deciding what to do next.
Nafisa Ali Sodhi said her treatment protocol has changed and she is now receiving targeted therapy.
She said a PET/CT scan suggested that her ovarian or peritoneal cancer had progressed.
The scan reportedly showed new cancer deposits on the surface of the liver.
Targeted therapy focuses on specific molecular changes, while chemotherapy broadly attacks rapidly dividing cells.
Doctors say treatment decisions depend on imaging, symptoms, overall health, prior response, and biomarker or molecular testing.
- Who
- Actor Nafisa Ali Sodhi and the doctors explaining her treatment.
- What
- Sodhi’s cancer treatment has changed to targeted therapy after a PET/CT suggested progression of ovarian or peritoneal cancer.
- When
- Recently, according to her Instagram post and the article.
- Where
- Sodhi shared the update on Instagram; the scan indicated disease on the surface of the liver.
- Why
- The reported scan suggested that the cancer had grown or appeared in a new area, prompting a change in the treatment approach.
- Patient
- Nafisa Ali Sodhi
- Cancer described
- Ovarian or peritoneal cancer
- New treatment
- Targeted therapy
- Scan finding
- New deposits on the surface of the liver
- Meaning of progression
- Cancer growth or new areas of disease despite treatment
- Treatment eligibility
- May require biomarker or molecular testing
- Clinical assessment
- Doctors compare imaging with earlier scans and consider symptoms, examination, and overall health